Abstract:Invasive fungal infections caused by drug-resistant organisms are an emerging threat to heavily immunosuppressed patients with hematological malignancies. Modern early antifungal treatment strategies, such as prophylaxis and empirical and preemptive therapy, result in long-term exposure to antifungal agents, which is a major driving force for the development of resistance. The extended use of central venous catheters, the nonlinear pharmacokinetics of certain antifungal agents, neutropenia, other forms of intense immunosuppression, and drug toxicities are other contributing factors. The widespread use of agricultural and industrial fungicides with similar chemical structures and mechanisms of action has resulted in the development of environmental reservoirs for some drug-resistant fungi, especially azole-resistant Aspergillus species, which have been reported from four continents. The majority of resistant strains have the mutation TR34/L98H, a finding suggesting that the source of resistance is the environment. The global emergence of new fungal pathogens with inherent resistance, such as Candida auris, is a new public health threat. The most common mechanism of antifungal drug resistance is the induction of efflux pumps, which decrease intracellular drug concentrations. Overexpression, depletion, and alteration of the drug target are other mechanisms of resistance. Mutations in the ERG11 gene alter the protein structure of C-demethylase, reducing the efficacy of antifungal triazoles. Candida species become echinocandin-resistant by mutations in FKS genes. A shift in the epidemiology of Candida towards resistant non-albicans Candida spp. has emerged among patients with hematological malignancies. There is no definite association between antifungal resistance, as defined by elevated minimum inhibitory concentrations, and clinical outcomes in this population. Detection of genes or mutations conferring resistance with the use of molecular methods may offer better predictive values in certain cases. Treatment options for resistant fungal infections are limited and new drugs with novel mechanisms of actions are needed. Prevention of resistance through antifungal stewardship programs is of paramount importance.

Antifungal resistance, combinations and pipeline: oh my!

New antifungal strategies: drug combination and co-delivery

Optimising the Treatment of Invasive Candidiasis – A Case for Combination Therapy

Antifungal drugs: What brings the future?

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

Antifungal pipeline: Is there light at the end of the tunnel?

Reassessment of the role of combination antifungal therapy in the current era

Synergistic Combinations of Antifungals and Anti-Virulence Agents to Fight Againstcandida Albicans

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox

Combination of antifungal therapy

Drug repurposing strategies in the development of potential antifungal agents

A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species

Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species

Advancements and challenges in antifungal therapeutic development

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies

Antifungal drug resistance: do molecular methods provide a way forward?

Old and new strategies in therapy and diagnosis against fungal infections